A retrospective analysis suggests that patients with NSCLC who harbour specific HER2 mutations may benefit from certain anti-HER2 treatments

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harbouring specific HER2 protein mutations. Read more here.

Study mentioned: Mazières J, et al. Lung Cancer That Harbors a HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. J Clin Oncol. 2013 Apr 22. [Epub ahead of print] PMID: 23610105